

November 13, 2009

**Otsuka Holdings announces
“Research and Development” website opens
November 13, 2009**

Tokyo Japan – Otsuka Holdings Co., Ltd. (Head office: Chiyoda-ku, Tokyo, Japan; President and Representative Director, CEO: Tatsuo Higuchi, "Otsuka Holdings") announces the opening on November 13 of a new website content, “Research and Development” <http://www.otsuka.com/en/rd/>, on its corporate website.

The site introduces main research and development activities and facilities of the Otsuka Group’s four business segments, pharmaceuticals, nutraceuticals*, consumer products and other businesses. A list of the Group’s pharmaceutical compounds in various stages of clinical development (“Product Pipeline”) which will be updated regularly is available on the site.

*nutraceuticals: nutrition + pharmaceuticals

Under the corporate philosophy of 'Otsuka—people creating new products for better health worldwide', Otsuka Holdings shares Otsuka’s mottoes “*JISSHO*” (Proof through Execution) and “*SOZOSEI*” (Creativity), aiming to cultivate a culture and a dynamic corporate climate reflecting our vision as a health-care company and develop innovative and creative products that contribute to the well-being of people around the world.

For US customers

Otsuka Otsuka Holdings Co., Ltd.

HOME Japanese

About Our Group News Corporate Information Financial Information **Research and Development** Social Responsibility

HOME > Research and Development

Research and Development

Based on our corporate philosophy of 'Otsuka - people creating new products for better health worldwide', the Otsuka Group conducts diversified research and development activities aimed at improving health and wellness, taking a long-term approach to changes in the health-care environment. Following is a brief overview of the research and development activities of our main operating companies.

- Pharmaceuticals**
Our comprehensive approach to pharmaceutical research and development ranges from diagnosis to treatment of diseases targeted at unmet medical needs.
- Nutraceuticals**
Expertise developed through our pharmaceuticals business is applied to the research and development of products that aid in the maintenance and improvement of day-to-day well-being.
- Consumer Products**
The Otsuka Group is engaged in the research and development of original and unique products in the food and beverage field.
- Other Businesses**
Research and development initiatives extend to chemical products, agrichemical products and electronic equipment.

R&D site
Top Page

Copyright(C) 2009 Otsuka Holdings Co.,Ltd. All

R&D site
Major R&D Facilities

For US customers

Otsuka Otsuka Holdings Co., Ltd.

HOME Japanese

About Our Group News Corporate Information Financial Information **Research and Development** Social Responsibility

HOME > Research and Development > Pharmaceuticals > Major R&D Facilities

Major R&D Facilities

The Otsuka Group has built a network of research centers worldwide, developing a global structure for the research and development of innovative new products to aid in the treatment of diseases and support day-to-day well-being.

Preclinical research is conducted in Japan, the US and China, with clinical development utilizing a network spanning Japan, the US, Europe and Asia.

- Otsuka Pharmaceutical
- ◆ Otsuka Pharmaceutical Factory
- ▲ Taiho Pharmaceutical
- Preclinical Research
- Clinical Development

GERMANY
● Otsuka Frankfurt Research Institute GmbH

CHINA
● Otsuka Shanghai Research Institute
● Otsuka Beijing Research Institute

JAPAN
● Tokushima
● First Institute of New Drug Discovery
● Third Institute of New Drug Discovery
● Microbiological Research Institute
● Medical Chemistry Research Institute
● Tokushima Research Institute
● Formulation Research Institute
● Quetsa Research Institute
● Institute of Biomedical Innovation
● R&D department of Diagnostic Division
● Tokushima Research Center

Shiga
● Fujii Memorial Research Institute

Hyogo
● Ako Research Institute

Saitama
▲ Drug Discovery Research Center
▲ CMC Research Center

U.S.A.
● Otsuka Maryland Medicinal Laboratories, Inc.
◆ New Product and Business Development US Office
● Otsuka Pharmaceutical Development & Commercialization Inc.
▲ TAIHO PHARMA U.S.A., INC.

Tokyo
● R&D department of Diagnostic Division
▲ Clinical Research & Development Center
◆ Research and Development Center
◆ Clinical Development Department

Osaka
● Headquarters of New Product Evaluation and Development
● Clinical Development Department, Division of Dermatologicals & Ophthalmologicals

Drug Discovery Research Center
Hanno Research Institute

Tokushima Research Institute

Otsuka Maryland Medicinal Laboratories, Inc.

▲ Back to top

Otsuka Group - Pipeline Information

(as of September 30, 2009)

Development Code/ Product name	Nonproprietary name	Origin	Category	Indication/Dosage form	Country/ Region	Status
Central nervous system						
OPC-14597 (ABILIFY*)	Aripiprazole	Otsuka Pharmaceutic.	Dopamine partial agonist	Schizophrenia in adolescents/Oral	EU	Approved
				Autism/Oral	US	Filed
				Adjunctive therapy for major depressive disorder/Oral	EU	Filed
				Schizophrenia/Depot injection	US, EU	Phase III
				Manic episode associated with bipolar I disorder/ Oral	JP	Phase III
				Adjunctive therapy for major depressive disorder/Oral	JP	Phase III
				Tourette syndrome/Oral	Korea	Phase III
L059 (KEPPRA*)	Levetiracetam	UCB	Anti-epileptic drug	Epilepsy (partial onset seizures)/Oral	JP	Filed
SPM-962 (NEUPRO*)	Rotigotine	UCB	Dopamin agonist	Parkinson's disease/Patch	JP	Phase III
				Restless legs syndrome/Patch	JP	Phase II
OPC-34712		Otsuka Pharmaceutic.	Dopamin partial agonist	Adjunctive therapy for major depressive disorder/Oral	US	Phase II
				Schizophrenia/Oral	US, EU	Phase II
Cardiovascular						
OPC-41061 (SAMSCA*)	Tolvaptan	Otsuka Pharmaceutic.	Vasopressin V2-receptor antagonist	Hyponatremia/Oral	US	Approved
				Hyponatremia/Oral	EU	Approved
				Cardiac edema/Oral	JP	Filed
				Autosomal dominate polycystic kidney disease/Oral	Global	Phase III
				Hepatic edema/Oral	JP	Phase II
				Hyponatremia/Oral	China	Phase II

Otsuka Group - Pipeline Information

(as of September 30, 2009)

Development Code/ Product name	Nonproprietary name	Origin	Category	Indication/Dosage form	Country/ Region	Status
Anti-cancer and cancer-supportive care						
ABI-007	Albumin-bound nanoparticle paclitaxel	Abraxis Bioscience	Anti-cancer (nanoparticle)	Breast cancer/Injection	JP	Filing in process
				NSCLC/Injection	JP	Phase III
				Gastric cancer/Injection	JP	Phase II
PALO	Palonosetron	Helsinn Healthcare	5-HT3 receptor antagonist	Antiemetic (nausea and vomiting)/ Injection	JP	Filing in process
OVF	Fentanyl	Cephalon	Narcotic analgesic	Cancer pain/Oral	JP	Phase III
S-1		Taiho	Anti-cancer (Anti-metabolite)	Gastric cancer/Oral	US, EU	Phase III
				Uterocervical cancer/Oral	JP, Asia	Phase III
				Pancreatic cancer, NSCLC/Oral	US	Phase II
				Prostatic, renal cell, hepatocellular cancer/Oral	JP	Phase II
TSU-68		SUGEN	Anti-cancer (Molecularly-targeted drug)	Hepatocellular carcinoma/Oral	JP	Phase II
				Breast cancer/Oral	JP, Asia	Phase II
TAC-101	Amsilarotene	Taiho	Anti-cancer (Molecularly-targeted drug)	Hepatocellular carcinoma/Oral	JP, US	Phase II
TAS-102		Taiho	Anti-cancer (Anti-metabolite)	Colorectal cancer/Oral	JP, US	Phase II
TAS-106		Taiho/SRI	Anti-cancer (Anti-metabolite)	Carcinoma of head and neck/ Injection	US, Asia	Phase II
TAS-108		Taiho	Hormone agent	Breast cancer/Oral	JP, US	Phase II
TAS-109		Taiho	Anti-cancer (Anti-metabolite)	Colorectal cancer/Injection	US	Phase II
OIF	Interferon α	Hayashibara Biochemical Labs	Natural interferon α	Highly advanced hepatocellular carcinoma (combination with 5- FU)/Injection	JP	Phase II
SATIVEX*		GW Pharmaceuticals	Cannabinoid (THC, CBD)	Cancer pain/Oral spray	US	Phase II
OPB-31121		Otsuka Pharmaceutic.	Anti-cancer	Anti Cancer/Oral	US, Asia	Phase I

Otsuka Group - Pipeline Information

(as of September 30, 2009)

Development Code/ Product name	Nonproprietary name	Origin	Category	Indication/Dosage form	Country/ Region	Status
Other areas						
FRG-8813	Lafutidine	Fujirebio	H2-receptor antagonist	Reflux esophagitis/Oral	JP	Filing
P4	Propiverine Hydrochloride	Apogepha	Therapeutic drug for urinary incontinence and frequency	Overactive bladder/Oral	JP	Filing
CDP870 (CIMZIA*)	Certolizumab pegol	UCB	PEGylated anti-TNF α drug	Crohn's disease/Injection	JP	Filing in process
				Rheumatoid arthritis/Injection	JP	Phase III
OPC-12759	Rebamipide	Otsuka Pharmaceutical	Mucin-production enhancing agent	Dry eyes/Eye drops	JP, US	Phase III
ONGLYZA*	Saxagliptin	Bristol-Myers Squibb	DPP-IV inhibitor	Type2 Diabetes/Oral	JP	Phase II/III
OPC-67683		Otsuka Pharmaceutical	Anti-tuberculosis agent	Multidrug-resistant Tuberculosis/Oral	Global	Phase II
OPC-6535	Tetomilast	Otsuka Pharmaceutical	Anti-inflammatory agent	Crohn's disease/Oral	JP	Phase II/III
				COPD/Oral	JP, US, China Korea	Phase II
TAC-201		Meiji Dairies Corporation	Recombinant peptide for immunotherapy of Japanese cedar pollinosis	Cedar pollen allergy/Injection	JP	Phase II

Diagnostics

ODK-0501 (Rapirun pneumococcus)		Otsuka Pharmaceutical	Diagnostic agent of pneumococcus infection	Extracorporeal diagnostic agent	JP	Filed
OMR-12200 (FerriSelts)	Ferric ammonium citrate	Otsuka Pharmaceutical	Oral contrast medium for gastrointestinal tract MRI	Magnetic Resonance cholangiopancreatography/Oral	JP	Filed
ODK-0702 (Rapirun H.pylori Stick)	H.pylori antibody kit	Otsuka Pharmaceutical	Diagnostic agent of H.pylori infection	Extracorporeal diagnostic agent	JP	Filed

Note 1: Otsuka Group, in principle, discloses the compounds which are at a later development stage than Phase II clinical trial in the Pipeline. In addition, some compounds such as anti-cancer agents are disclosed from Phase I clinical trial in the list.

Note 2: Product names with asterisk "*" are the names used outside Japan.